Scientific Board

Leader in developing, producing
and commercializing pharmacogenetics
tests for cancer precision medicine.

Stefano Pileri

Chair of the board

Former Full-Professor of Pathology, Bologna University and former Director of the Haematopathology Divisions of Bologna University and European Institute of Oncology (IEO-IRCCS, Milan). Currently, Research Leader of the IEO Haematopathology Division and President of the Scientific Board of Diatech Pharmacogenetics.

Author of 1,186 scientific reports (711 quoted in PubMed or in press with a total IF of 6,260.550) and regular invited speaker at International Meetings. Co-author of the „Revised European American Lymphoma Classification“ (1994) and the International Consensus Classification (2022). Co-editor and Co-author of the fourth Edition of the WHO Classification of Lymphomas and Leukaemias (in 2008) and its revision in 2017. Past-President of the European Association for Haematopathology. H.C. degree in Medicine at Athens University. Ranked 22nd among the Top Italian Scientists in the field of Medicine. H-index = 129. Past-President of Bologna Rotary Club (2004-2005).

Reinhard Büttner

Professor Buettner received his M.D. from the Ludwig-Maximilians-University in Munich/Germany and worked as a postdoctoral researcher at the Gene-Center LMU Munich and the MD Anderson Cancer Center, Houston/Texas. After his residency, he was appointed associate professor at the RWTH Aachen and served as Full professor and director of the Institute of Pathology at Bonn and Cologne University Medical Centers.

Reinhard Buettner is a pathologist with specific expertise in Molecular Pathology and Lung Pathology and serves as one of the Speakers of the German Network Genomic Medicine nNGM and as a member of the National Academy of Sciences, Leopoldina.

He has published more than 600 original publications, served as Dean of the Medical Faculty at Bonn University, as a member of the Board of Trustees, German Cancer Aid, the past president of the German Division of the International Academy of Pathology, and will serve as the president of the German Cancer Congress, DKK 2024 in berlin.

Riccardo Dalla-Favera

Professor of Pathology & Cell Biology, and Director of the Institute for Cancer genetics at Columbia University, New York. Riccardo Dalla-Favera is best known for his studies on the genetic alterations involved in the pathogenesis of human cancer, in particular, human B-cell lymphoma. His research team has contributed significantly to the understanding of normal B cell function, directly impacting the diagnostics and therapeutic targeting of B cell malignancies including Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, and Chronic Lymphocytic Leukemia.

Dr. Dalla-Favera’s work is widely recognized with numerous National and International prizes and awards, including two NIH MERIT Awards, the 2006 William Dameshek Prize for Outstanding Contribution to Hematology from The American Society of Hematology, the 2012 Alfred Knudson Award from the National Cancer Institute, and in 2014, the OncLive Giants of Cancer Care Award. Dr. Dalla-Favera is an elected member of the National Academy of Medicine and the National Academy of Sciences, USA

Umberto Malapelle

Umberto Malapelle is an Associate Professor at the Department of Public Health, School of Medicine, University of Naples Federico II. Currently is the Chair of the Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples and the Scientific Secretary of the International Society of Liquid Biopsy.

His main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor. Moreover, he has developed skills in tailoring Next Generation Assays for a number of different applications with a special focus on the simultaneous detection of clinically relevant alterations (i.e., EGFR mutations, ALK translocation, PD–L1 expression) in the routine setting including handling of different sample types, such as tissues and/or liquid biopsy specimens.

Bertrand Nadel

Currently an INSERM Research Director and lab head at the Centre d’Immunologie de Marseille-Luminy (CIML) France.

With more than 30 years of experience in onco-immunology research, Bertrand Nadel has gained, since 2015,  extensive parallel experiences in the creation, management, and direction of federative academic structures, bridging public research and industry, first as Director of the Canceropole of southern France PACA region (2015-2017) and as Director of a Carnot Institute (2018-present).

During the last 10 years, He has acquired the appetence and know-how for building, developing, professionalizing, and managing networks and fruitful partnerships between academic research (basic, translational, non-clinical, and clinical) and biopharma.

Mr. Nadel’s lab (http://www.ciml.univ-mrs.fr/science/lab-bertrand-nadel/home) focuses on the (epi)genetic mechanisms of oncogenesis in human lymphoma/leukemia and aims to identify bio-markers, targets and innovative therapeutic approaches in partnership with clinics and Biopharma.

Among others, they contributed to deciphering the natural history of follicular lymphoma pathogenesis and are now hunting the precursor cells seeding relapses using state-of-the-art omics technologies. The CALYM Carnot Institute on lymphoma (http://www.calym.org/), is a nationwide consortium aiming to foster innovation, research, and development between academia and industry.

Raul Rabadan

Raul Rabadan is the Gerald and Janet Carrus Professor in the Department of Systems Biology at Columbia University. He is the director of the Program for Mathematical Genomics (PMG) and was the director of the Center for Topology of Cancer Evolution and Heterogeneity at Columbia (2015-2021). From 2001 to 2003, Dr. Rabadan was a fellow at the Theoretical Physics Division at CERN, the European Organization for Nuclear Research, in Geneva, Switzerland. In 2003 he joined the Theoretical Physics Group of the School of Natural Sciences at the Institute for Advanced Study at Princeton, New Jersey.

From 2006 to 2008, Dr. Rabadan was the Martin A. and Helen Chooljian Member at The Simons Center for Systems Biology at the Institute for Advanced Study. At Columbia, he has put together a highly interdisciplinary team of researchers from the fields of mathematics, physics, computer science, engineering, and medicine, with the common goal of solving pressing biomedical problems through quantitative computational models. Rabadan’s current interest focuses on uncovering patterns of evolution in biological systems—in particular, viruses and cancer.

Giovanni Scambia

Scientific Director of Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Full Professor of Obstetrics and Gynaecology, Catholic University, Rome, Italy, Professor Scambia is specialized in gynaecological cancer treatment and research. He has studied and developed innovative surgical approaches for the cure of gynecological cancers and has been invited professor in several academic hospitals both in Europe and outside Europe. He is considered an opinion leader in the field of gynecologic oncology. He has published approximately 1500 scientific works relating to topics of experimental and clinical interest in international journals.

President of Board of Directors of the European Society for Gynaecological Endoscopy of E.S.G.E., Member and Vice President 1st Section of Consiglio Superiore di Sanità, Italiana Ministry of Health, Member of the Medical Professional Negligence Commission, Ministry of Justice, he is also Coordinator of the guidelines on the conservative therapy of uterine tumors and ovarian tumors of “European Society of Gynaecological Oncology – European Society of Human Reproduction and Embriology – European Society for Gynaecological Endoscopy”.